Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Company Overview - The company has undergone significant transformation in 2025, with positive developments stemming from strategic setups made in previous years [1] - The company is now valued at approximately $14.5 billion and operates as a public biopharma entity focused on late-stage drug development for underserved patient populations [2] Progress and Achievements - The company's portfolio has advanced meaningfully this year, contributing to heightened excitement and optimism within the organization [3]